Abstract
Guidelines recommend anticoagulation to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). In the real world, this treatment is underused, probably for pharmacologic limitations of vitamin-K-antagonist (VKA). The New Oral Anticoagulants (NOAC) overcome many limitations of VKA. The aim of this study was to assess if, after introduction of NOAC, anticoagulated patients are increased. We performed an observational retrospective cohort study about patients with NVAF, hospitalized in Internal Medicine or Geriatrics for any cause in two years, before and after the marketing of NOAC. The results showed: 640 patients enrolled (289 in 2012, 351 in 2015), elderly population (83+7), males 42% females 58%, high morbidity, high thromboembolic (CHA2DS2VASc 5+1,6) and haemorrhagic (HASBLED 2.7+1.2) risks, with frequent chronic renal disease (51% stage >3) and contraindications to anticoagulants (21,6%). Therapy at discharge 2012 vs 2015: VKA 124/289 (43%) vs VKA or NOAC 187/351 (53%) (p<0,01); antiplatelet 114/289 (39%) vs 70/351 (20%) (p<0,0001). For the high comorbidity, frequent use of LMWH: 42/289 (15%) in 2012 vs 77/351 (22%) in 2015. NOAC have increased the adherence to guidelines in prescribing oral anticoagulants in patients with NVAF.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
